Skip to main content

Advertisement

Table 3 Maintenance of device mastery and inhalation errors after 12 weeks in the longitudinal phase

From: Evaluation of inhaler technique and achievement and maintenance of mastery of budesonide/formoterol Spiromax® compared with budesonide/formoterol Turbuhaler® in adult patients with asthma: the Easy Low Instruction Over Time (ELIOT) study

Outcome BF Spiromax (N = 151) BF Turbuhaler (N = 154) Odds ratio (95% CI) P-valuea
HCP-observed errors
 Patients without errors (inhalations 1 & 2) (co-primary endpoint), n (%) 89 (58.9) 82 (53.2) 1.26 (0.80–1.98)c 0.316
 Patients without errors related to dose preparation (inhalation 1), n (%) 128 (84.8) 111 (72.1) 2.16 (1.22–3.80)c 0.007
 Patients without errors related to the inhalation maneuver (inhalation 1), n (%) 117 (77.5) 116 (75.3) 1.13 (0.66–1.92)c 0.657
 Number of HCP-observed errors per patient, mean (SD) 0.50 (0.67) 0.81 (1.10) 0.61 (0.44–0.84)d 0.003
HCP-observed errors reassessed by video expert review (exploratory analysis)
 nb 119 124
 Total number of errors observed by video expert 56 124
 Patients without errors (inhalations 1 & 2), n (%) 79 (66.4) 60 (48.4) 2.11 (1.25–3.54)c 0.005
 Number of video expert assessed errors per patient, mean (SD) 0.47 (0.78) 1.00 (1.26) 0.47 (0.34–0.64)d < 0.001
  1. BF budesonide formoterol, CI confidence interval, HCP healthcare professional, SD standard deviation
  2. aDerived from Chi-squared test
  3. bNote: Six patients for whom errors were reassessed by independent video review were not included in the full analysis set; data for these patients are not shown in the table
  4. cEstimated from logistic regression models
  5. dEstimated from negative binomial regression model